How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Newborn Disease Screening Market
- By Screening Method: Tandem Mass Spectrometry (MS/MS), Enzyme Assay, Molecular Genetic Testing, Immunoassay, Next-Generation Sequencing (NGS)
- By Disease Type: Metabolic Disorders, Endocrine Disorders, Hemoglobinopathies, Cystic Fibrosis, Severe Combined Immunodeficiency (SCID)
- By Sample Type: Dried Blood Spot (DBS), Cord Blood, Urine Samples, Saliva Samples
- By End User: Hospitals and Clinics, Diagnostic Laboratories, Government Screening Programs, Research Institutes
- By Technology Platform: Fluorometric Assays, Chromatography, Polymerase Chain Reaction (PCR), Microarray Technology
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Tandem Mass Spectrometry (MS/MS) leads By Screening Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Newborn Disease Screening Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Screening Method 5
Disease Type 5
Sample Type 4
End User 4
Technology Platform 4
Companies profiled
PerkinElmer Inc.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Agilent Technologies Inc.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Quidel Corporation
Luminex Corporation
Genetic Technologies Limited
Natus Medical Incorporated
BioMérieux SA
Danaher Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →PerkinElmer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bio-Rad Laboratories Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Agilent Technologies Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →F. Hoffmann-La Roche Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Quidel Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Luminex Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Genetic Technologies Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Natus Medical Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →BioMérieux SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Danaher Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Illumina Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Becton
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Dickinson and Company (BD)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Eurofins Scientific
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,604M by 2033 · 3.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Tandem Mass Spectrometry (MS/MS)38.5
- Enzyme Assay19.5
- Molecular Genetic Testing17.2
- Immunoassay14.0
- Next-Generation Sequencing (NGS)10.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$643.2M → $803.3M · 2.8%
Europe$448.3M → $585.8M · 3.4%
Asia Pacific$409.3M → $504.0M · 2.6%
Latin America$253.4M → $345.9M · 4.0%
Middle East and Africa$194.9M → $240.7M · 2.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.632026
3.642027
3.662028
3.682029
3.682030
3.692031
3.712032
3.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- PerkinElmer Inc.26.6
- Thermo Fisher Scientific Inc.16.7
- Bio-Rad Laboratories Inc.7.3
- Agilent Technologies Inc.4.9
- F. Hoffmann-La Roche Ltd.11.4
- Abbott Laboratories5.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Screening Method8.3%
Disease Type27.3%
Sample Type19.1%
End User17.4%
Technology Platform27.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.4
- Europe23.6
- Asia Pacific20.3
- Latin America13.9
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| PerkinElmer Inc. | 74 | 95 | 76 | 99 | 94 | 92 | 88 |
| Thermo Fisher Scientific Inc. | 71 | 76 | 75 | 83 | 81 | 76 | 77 |
| Bio-Rad Laboratories Inc. | 75 | 70 | 66 | 75 | 65 | 69 | 70 |
| Agilent Technologies Inc. | 57 | 64 | 73 | 57 | 80 | 59 | 65 |
| F. Hoffmann-La Roche Ltd. | 65 | 64 | 67 | 58 | 64 | 60 | 63 |
| Abbott Laboratories | 57 | 55 | 64 | 62 | 52 | 49 | 57 |
| Quidel Corporation | 57 | 61 | 62 | 43 | 48 | 60 | 55 |
| Luminex Corporation | 51 | 44 | 47 | 53 | 48 | 40 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- PerkinElmer Inc.
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| PerkinElmer Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Thermo Fisher Scientific Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Bio-Rad Laboratories Inc. | ◐ | ✓ | − | ◐ | ◐ | ✓ |
| Agilent Technologies Inc. | − | − | ◐ | ◐ | ✓ | − |
| F. Hoffmann-La Roche Ltd. | ◐ | ◐ | ◐ | − | − | − |
| Abbott Laboratories | − | ◐ | − | ◐ | ◐ | ◐ |
| Quidel Corporation | ◐ | ◐ | ◐ | − | ◐ | − |
| Luminex Corporation | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1PerkinElmer Inc.88
2Thermo Fisher Scientific Inc.77
3Bio-Rad Laboratories Inc.70
4Agilent Technologies Inc.65
5F. Hoffmann-La Roche Ltd.63
6Abbott Laboratories57
7Quidel Corporation55
8Luminex Corporation47
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
PerkinElmer Inc.
Challenger2
Strong scale, closing on the leaders.
Thermo Fisher Scientific Inc.Bio-Rad Laboratories Inc.
Contender3
Focused players with pockets of strength.
Agilent Technologies Inc.F. Hoffmann-La Roche Ltd.Abbott Laboratories
Niche2
Specialists in a single segment or region.
Quidel CorporationLuminex Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Screening Method in North America, then scale across Newborn Disease Screening Market — a $234M beachhead inside a $3.72B market.
Beachhead (SOM)$234Mobtainable near-term
Serviceable (SAM)$1.27Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Tandem Mass Spectrometry (MS/MS)
Best fit — highest urgency & budget in Screening Method.
Economic buyer77 fit
Enzyme Assay
Strong fit — clear ROI and a fast path to value.
End user67 fit
Molecular Genetic Testing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Screening Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Disease Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sample Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel25%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Screening Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Newborn Disease Screening Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified23%
Evaluation15%
Closed-won6%
$15.5KCAC
$83KLTV
5.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Newborn Disease Screening Market is a resilient opportunity — $971M by 2033, compounding at 4.1%.
TAM · 2025$703Mtoday
TAM · 2033$971Mforecast
CAGR4.1%2027–2033
Cumulative$7.47Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$971MTotal addressable market
SAM$367MServiceable available market
SOM$61MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.1% CAGR
Demand compounds through 2033, outpacing GDP across Screening Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Screening Method moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$971MLarge & growingTAM by 2033 at 4.1% CAGR
$367MServiceable nowreachable with today’s model
$61MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$757MBear2.7% CAGR
$971MBase4.1% CAGR
$1.24BBull5.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Disease Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Newborn Disease Screening Market — a $8.05B market by 2033. Plan: grow share from 6.9% to 11.9%.
Market size · 2033$8.05Btotal addressable
Market CAGR7.5%2027–2033
Target share11.9%from 6.9% today
Revenue ambition$958Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 11.9% | On track |
| Revenue | $503M | $958M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 29.2% | 43.2% | Ahead |
| Customer retention | 86.0% | 95.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Screening Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Disease Type capability
A defensible second engine — invest in Disease Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Screening Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Disease Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $104M capacity & capability investment
- Greenlight bolt-on M&A in Disease Type
- Authorise North America expansion plan
- Fund R&D program for Screening Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Newborn Disease Screening Market conversation — a $1.14B market you can size, segment and defend in minutes.
Market size · 2033$1.14Btotal opportunity
Growth3.5%CAGR to 2033
Addressable buyers1,296+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Screening Method
Goal Grow share in Screening Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 2 mopayback period
$44K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
PerkinElmer Inc.Thermo Fisher Scientific Inc.Bio-Rad Laboratories Inc.Agilent Technologies Inc.F. Hoffmann-La Roche Ltd.Abbott LaboratoriesQuidel CorporationLuminex Corporation+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Newborn Disease Screening Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Newborn Disease Screening Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Newborn Care Service Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportNewborn Blood Spot Test Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportNewborn Blood Spot Screening Card Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportNewborn Blood Screening Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportNewborn Bed Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportNewborn Artificial Resuscitator with Valve Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportNewborn and Prenatal Genetic Testing Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportNevirapine API Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportNeutropenia Biologic Drug Treatment Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportNeutron Low Scattering Irradiator Market
Market size, share, segmentation and regional forecast.
$982M market · 2025 base year
View reportNeutron Dosimeter Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportNeutron Capture Therapy of Cancer Market
Market size, share, segmentation and regional forecast.
$383M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.